To further validate the importance of PAD4 activation and to test the potential role of PAD4 inhibitors as potential therapies, we employed pretreatment with GSK484 in our experimental murine model of nonthermal burn-related extrapulmonary ARDS. The gene discussed is PADI4; the disease is acute respiratory distress syndrome.